Abbott signals recovery in device sales as hospital staff shortages ease (April 19)
Reuters
Published Apr 19, 2023 07:20AM ET
Updated Apr 20, 2023 11:18AM ET
(This April 19 story has been corrected to say Third Bridge is an "investment research firm", not "investment consulting firm", in paragraph 9)
By Khushi Mandowara and Leroy Leo
(Reuters) - Abbott Laboratories (NYSE:ABT) said on Wednesday most delayed non-urgent medical procedures had resumed globally three years into the COVID-19 pandemic as hospital staff shortages eased and customers became regular with check-ups, sending shares up 7%.
The much-awaited recovery in elective surgeries led the company to effectively raise forecast for its core business, even as COVID testing-related sales were seen falling sharply.
The company is the second major medical device maker to signal a recovery after rival Johnson & Johnson (NYSE:JNJ) on Tuesday posted better-than-expected sales for the business.
Abbott's upbeat commentary lifted shares of other medical device makers Medtronic (NYSE:MDT), Stryker (NYSE:SYK), Zimmer Biomet and Boston Scientific Corp (NYSE:BSX) by 2%-4% in morning trade.
Abbott's stronger outlook for its non-COVID business was the main takeaway as investors had priced in a fall in COVID testing sales, J.P. Morgan analyst Robbie Marcus said in a note.
The Illinois-based company lowered its outlook for COVID testing sales this year to $1.5 billion from the $2 billion it forecast in January, but retained its annual adjusted profit outlook at $4.30-$4.50 per share, indicating growth in its non-COVID core business, including medical devices.
"I think it is sustainable. I don't think it's a bolus of backlog," Abbott CEO Robert Ford said about the recovery in its core business.
Medical devices - Abbott's largest segment - clocked an 8.5% rise in sales to $3.90 billion, with $1.2 billion coming from glucose monitoring device Freestyle Libre. Analysts had estimated sales of $3.77 billion for the unit, according to Refinitiv data.
Still, George Congdon, an analyst with investment research firm Third Bridge, was skeptical. "I wouldn't read too much into one quarter of U.S. volume recoveries."
Get The News You Want
Staffing issues are now widespread in the U.S. hospitals, and could take a couple of years to fully wane, he said.
Abbott reported an adjusted profit of $1.03 per share, higher than analysts' average estimate of 99 cents.
Written By: Reuters
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.